Posts
December 21 2011
StemCells, Inc. announced the closing of their underwritten public offering in the amount of $10,000,000. EG&S acted as counsel to the Underwriter.
December 13 2011
PhotoMedex, Inc., a NASDAQ listed company, and Radiancy, Inc., a private Delaware company, announced the completion of their merger. Pursuant to the merger, the former stockholders of Radiancy received shares of Photomedex valued on the date of closing at approximately $235 million and collectively own approximately 75% of PhotoMedex, Inc. following the merger. Radiancy became a majority-owned subsidiary of PhotoMedex. EG&S acted as counsel to Radiancy.
December 13 2011
Cell Therapeutics Inc. announced the closing of their registered direct in the amount of $20,000,000. EG&S acted as counsel to the Placement Agent.
December 07 2011
Capitol C Holdings LLC announced the completion of its refinancing of senior secured debt with NCB, FSB. EG&S acted as counsel to Capitol C Holdings.
December 06 2011
Celsion Corporation announced the closing of their PIPE offering in the amount of $15,000,00. EG&S acted as counsel to the Placement Agent.
November 23 2011
IceWEB, Inc. announced the closing of their private placement in the amount of $1,750,000.00. EG&S acted as counsel to the Placement Agent.
November 16 2011
Adventrx Pharmaceuticals, Inc. (AMEX: ANX) announced the completion of its underwritten public offering of common stock and warrants in the amount of $17,000,000. EG&S acted as counsel to the underwriter.
November 16 2011
Bluff Point Associates Corp. announced the acquisition of a controlling interest in Connexin Software, Inc. of Connexin Software, Inc. for the amount of $6,375,000. EG&S acted as counsel to Bluff Point Associates Corp.